Identification of Multiple Sclerosis genetic markers leading to clinical benefits to affected patients [dataset]


Multiple Sclerosis (MS) is characterized by severe compromises to neuroimmune processes involving changes in immune cell function, soluble proteins and modulation of inflammatory processes. The introduction of therapeutic agents in the form of immunomodulators; interferon, phosphodiesterase inhibitors and Glatiramer acetate have proven to be useful to some extent in reducing the severity of MS. Herein the implications and effects of these molecules on the immune system in MS are reviewed. Additionally, the available evidence on the mode of action of neuropeptides in MS, their effectiveness on clinical measures, and current knowledge are also reviewed.

Data in SPSS software.

Associated publications:

Immunomodulators as therapeutic strategies for managing Multiple Sclerosis

Collection Period


Field of Research Code

110703, 110602, 100706

Access Rights

Contact Lotti_Tajouri@bond.edu.au to determine access conditions.